SAN DIEGO, April 4, 2019 /PRNewswire/ — RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, today announced its participation at the World Orphan Drug Congress 2019 being held in Maryland April 10-April 12th, 2019. Mutations in SCN2A are the most common cause of neurodevelopmental diseases such as severe epilepsy and autism, with numerous associated comorbidities and no known cure.
Steven Petrou, Ph.D., RogCon Co-Founder and head of The Florey Institute of Neuroscience, will present preclinical data on the company’s lead program, RC-222, an antisense oligonucleotide designed to down-regulate SCN2A, which was discovered by and is being developed with Ionis Pharmaceuticals, Inc. (Ionis), the leader in RNA-targeted drug discovery and development.
Presentation details are as follows:
Title: “Antisense Oligonucleotide Therapy for SCN2A Gain-of-Function Epilepsies”
Category: Next Generation Therapies Seminar
Date and Time: April 10th, 2019, 10:50 am-11:10 am EDT
Location: Gaylord National Harbor Hotel, Oxon Hill, Maryland
About SCN2A Mutations
Mutations in SCN2A (Nav1.2) are the most common cause of neurodevelopmental disease — however, at present there is no corrective therapy specifically for SCN2A patients. All current medications are focused primarily on symptomatic relief. Epilepsy and autism are the most prominent conditions but there are numerous comorbidities, including sensory dysfunction, movement/muscle disorders, intellectual disability, gastrointestinal complications, metabolic abnormalities and others.
About RogCon Biosciences
RogCon is a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, where no solutions currently exist. Mutations in SCN2A are the most common cause of neurodevelopmental disease, epilepsy, and autism, and there are numerous associated comorbidities. RogCon has amassed a group of world experts in genetic epilepsy research and drug development, with a focus on SCN2A, including collaborations with The Florey Institute of Neuroscience and with Ionis Pharmaceuticals, Inc. RogCon is developing a potentially disease-modifying therapy (RC-222) designed to down-regulate SCN2A. RC-222 is an antisense oligonucleotide (ASO) developed using Ionis’ proprietary antisense technology that is designed to treat the root cause of SCN2A-caused neurodevelopment disease. To learn more, please visit www.rogcon.com.
Investor and Media Contact:
SOURCE RogCon Biosciences